← SynDRA
MIVAVOTINIB
SynDRA canonical compound SYN0038677 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | SYK |
|---|
| Mechanism of action | spleen associated tyrosine kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- SYK INHIBITOR
- Tyrosine-protein kinase SYK inhibitor
- spleen associated tyrosine kinase inhibitor
Cross-references
Synonyms
- CB-659
- TAK-659 FREE BASE
- TAK-659F
- TAK-659 free base
- 8QR88H79VX
- TAK659
- mivavotinibum
- TAK659 Free Base
- syk-Inhibitor TAK659
- syk-Inhibitor TAK-659
- RefChem:1089763
- Spleen Tyrosine Kinase Inhibitor TAK659
- TAK-659
- Mivavotinib [USAN]
- TAK-659 HCl
- MIVAVOTINIB [INN]
- Mivavotinib (USAN/INN)
- TAK659 2HCl
- UNII-8QR88H79VX
- MIVAVOTINIB [WHO-DD]
- TAK-659 2HCl
- GTPL9600
- orb1705261
- SCHEMBL1987799
- SCHEMBL29422867
- MJHOMTRKVMKCNE-NWDGAFQWSA-N
- TAK-659 free base(Mivavotinib)
- GLXC-15199
- EX-A1401
- BDBM50204290
- NSC791967
- NSC791968
- WHO 10836
- AKOS040744760
- NSC-791967
- NSC-791968
- compound 3b [PMID: 27839918]
- NCGC00510693-02
- AC-35463
Look up MIVAVOTINIB in the interactive SynDRA portal →